《WHO基本药物示范目录》与我国《国家基本药物目录》动态调整程序比较与借鉴

Comparison and Reference of the Dynamic Adjustment Procedure for WHO Essential Medicine Demonstration List and National Essential Medicine List in China

目的:为完善我国《国家基本药物目录》动态调整程序提供参考。方法:梳理《WHO基本药物示范目录》和我国《国家基本药物目录》动态调整历史沿革及现状,将两者进行比较,找出差异,分析我国《国家基本药物目录》动态调整程序存在的问题。结果与结论:我国《国家基本药物目录》动态调整存在程序透明度较差、自上而下的效率较低、依靠专家主观因素较多、可操作性不强等问题。建议提高我国《国家基本药物目录》动态调整程序透明度,建立自上而下与自下而上相结合的动态调整程序,健全基本药物动态调整程序的配套制度,加强基本药物循证医学和药物经济学评价,优化专家库管理,以完善《国家基本药物目录》动态调整程序。

OBJECTIVE： To provide reference for the improvement of dynamic adjustment procedure for National Essential Medicine List in China. METHODS ： The history and current situation of dynamic adjustment procedure for WHO Essential Demonstration List and National Essential Medicine List in China were sorted out. RESULTS＆CONCLUSIONS： There are some problems in dynamic adjustment procedure for National Essential Medicine List in China, such as poor transparency, low top-down efficiency, various specialist＇ s subjective factor, weak operability. It is suggested to improve transparency of dynamic adjustment procedure, establish top-down and bottom-up dynamic adjustment procedure, promote support system, strengthen evidence-based medicine and pharmacoeconomic evaluation of essential medicine and optimize specialist database management so as to improve dynamic adjustment procedure for National Essential Medicine List in China.